Logo image
BRN2 is a non-canonical melanoma tumor-suppressor
Journal article   Open access   Peer reviewed

BRN2 is a non-canonical melanoma tumor-suppressor

Michael Hamm, Pierre Sohier, Valérie Petit, Jérémy Raymond, Véronique Delmas, Madeleine Le Coz, Franck Gesbert, Colin Kenny, Zackie Aktary, Marie Pouteaux, …
Nature communications, Vol.12(1), pp.3707-3707
12/2021
DOI: 10.1038/s41467-021-23973-5
PMCID: PMC8211827
PMID: 34140478
url
https://doi.org/10.1038/s41467-021-23973-5View
Published (Version of record) Open Access

Abstract

Abstract While the major drivers of melanoma initiation, including activation of NRAS/BRAF and loss of PTEN or CDKN2A , have been identified, the role of key transcription factors that impose altered transcriptional states in response to deregulated signaling is not well understood. The POU domain transcription factor BRN2 is a key regulator of melanoma invasion, yet its role in melanoma initiation remains unknown. Here, in a Braf V600E Pten F/+ context, we show that BRN2 haplo-insufficiency promotes melanoma initiation and metastasis. However, metastatic colonization is less efficient in the absence of Brn2. Mechanistically, BRN2 directly induces PTEN expression and in consequence represses PI3K signaling. Moreover, MITF, a BRN2 target, represses PTEN transcription. Collectively, our results suggest that on a PTEN heterozygous background somatic deletion of one BRN2 allele and temporal regulation of the other allele elicits melanoma initiation and progression.
Life Sciences

Details

Logo image